
-
'How to Train Your Dragon' holds top spot in N.America box office
-
Almeida wins time-trial to take Tour of Switzerland
-
Bublik sees off Medvedev to claim second title on grass in Halle
-
Feyi-Waboso banned for England tour to Argentina
-
US strikes on Iran: what we know
-
Alcaraz crowned king of Queen's for second time
-
US says strikes 'devastated' Iran's nuclear program
-
Bublik sees off Medvedev to claim fifth AFP title in Halle
-
Freed Belarus opposition figure urges Trump to help release all prisoners
-
Wave of syringe attacks mar France's street music festival
-
US intervention 'devastated' Iran's nuclear programme says Pentagon
-
Marc Marquez completes perfect Mugello weekend with Italian MotoGP triumph
-
Vondrousova warms up for Wimbledon with Berlin title
-
India still on top in first Test despite Brook fifty for England
-
Ukraine army chief vows to expand strikes on Russia
-
United behind Iran war effort, Israelis express relief at US bombing
-
Former England fast bowler David Lawrence dead at 61
-
At least three impacts in Israel during Iran missile attacks, 23 hurt
-
Trump says US strikes 'obliterated' Iran nuclear sites
-
Japan's high-tech sunscreens tap into skincare craze
-
Tesla expected to launch long-discussed robotaxi service
-
South Korea counts on shipbuilding to ease US tariff woes
-
Bombing Iran, Trump gambles on force over diplomacy
-
Trump says US attack 'obliterated' Iran nuclear sites
-
Itoje to Valetini: five to watch when the Lions face Australia
-
Wallabies confident but wary of wounded British and irish Lions
-
Utopia and fragile democracy at Art Basel fair
-
Freed Israeli hostage recounts 484-day nightmare in Gaza
-
River Plate frustrated by Monterrey in 0-0 stalemate
-
Panama cuts internet, cell phones in restive province
-
Tens of thousands join pro-Palestinian marches across Europe
-
Coach Penney unsure of return to Super Rugby champions Crusaders
-
Trump says US 'obliterated' Iran nuclear sites, threatens more
-
Olympic chief Kirsty Coventry's steeliness honed by hard knocks
-
Outgoing IOC president Thomas Bach faced mammoth challenges
-
Maro Itoje comes of age with Lions captaincy
-
Trump says US bombs Iran nuclear sites, joining Israeli campaign
-
In New York, Vermeer show reveals art of the love letter
-
Ex-members of secret US abortion group fear return to dark era
-
Trump says US launched 'very successful' attack on Iran nuclear sites
-
Man City squad must be trimmed: Guardiola
-
Minjee Lee grabs four-shot lead at 'brutal' Women's PGA Championship
-
Olympic balloon rises again in Paris
-
Inter Milan, Dortmund claim first wins at Club World Cup
-
South American teams lay down the gauntlet to Europe at Club World Cup
-
Fleetwood grabs PGA Travelers lead as top-ranked stars fade
-
'Lucky' Lamothe hat-trick guides Bordeaux-Begles into Top 14 final
-
Lamothe hat-trick guides Bordeaux-Begles into Top 14 final
-
UK PM Starmer says Kneecap should not perform Glastonbury
-
Inter Milan strike late to beat Urawa Reds at Club World Cup

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
G.AbuHamad--SF-PST